Rochester, NY – September 9, 2011. Vaccinex, Inc. announced today that it will present preclinical results from testing of an anti-SEMA4D antibody for the potential treatment of multiple sclerosis at the 2011 annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam, The Netherlands October 19-22. SEMA4D has been shown to induce growth cone collapse of neurons and to induce process extension collapse and apoptosis of oligodendrocytes. Furthermore, SEMA4D has been demonstrated to inhibit oligodendrocyte differentiation and myelination. Vaccinex has developed an anti-SEMA4D monoclonal antibody that prevents SEMA4D from engaging its cognate receptors PLEXINB1 and CD72. Vaccinex has shown that treatment with anti-SEMA4D MAbs attenuates the severity of EAE in several mouse EAE models. Data from preclinical studies will be presented.
SEMA4D signaling through PLXNB1 has also been implicated in several key mechanisms of tumor progression including angiogenesis. Using various tumor models we demonstrated that anti-SEMA4D antibody inhibits tumor growth and angiogenesis. A Phase I clinical trial assessing safety and tolerability in patients with advanced solid tumors was initiated in February 2011.
Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company’s patented ActivMAb® technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Vaccinex, on its own or with its partners, has advanced several antibodies from discovery and lead validation into IND-directed pre-clinical drug development. The company is headquartered in Rochester, NY, USA. For more information, please visit www.vaccinex.com.